What is HC Wainwright’s Estimate for MAZE FY2030 Earnings?

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Research analysts at HC Wainwright issued their FY2030 EPS estimates for Maze Therapeutics in a research note issued to investors on Monday, January 26th. HC Wainwright analyst A. Ghosh anticipates that the company will post earnings of $0.60 per share for the year. HC Wainwright currently has a “Buy” rating on the stock.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

MAZE has been the subject of several other research reports. Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Guggenheim restated a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a research report on Friday, December 19th. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, January 25th. BTIG Research lifted their price target on shares of Maze Therapeutics from $37.00 to $46.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Finally, Wells Fargo & Company assumed coverage on Maze Therapeutics in a research report on Thursday, December 4th. They set an “overweight” rating and a $55.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $44.50.

Maze Therapeutics Stock Performance

Shares of NASDAQ MAZE opened at $45.00 on Wednesday. Maze Therapeutics has a 1 year low of $6.71 and a 1 year high of $47.36. The firm has a market cap of $2.17 billion and a P/E ratio of -2.15. The stock has a fifty day moving average price of $40.71 and a two-hundred day moving average price of $28.79.

Insider Transactions at Maze Therapeutics

In related news, insider Atul Dandekar sold 72,400 shares of the company’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the transaction, the insider directly owned 10,503 shares of the company’s stock, valued at approximately $426,001.68. The trade was a 87.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Harold Bernstein sold 25,156 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $40.20, for a total value of $1,011,271.20. The SEC filing for this sale provides additional information. Insiders sold a total of 172,500 shares of company stock valued at $7,002,267 over the last quarter.

Institutional Investors Weigh In On Maze Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CWM LLC acquired a new position in shares of Maze Therapeutics during the 2nd quarter valued at about $28,000. GF Fund Management CO. LTD. acquired a new position in Maze Therapeutics during the fourth quarter valued at approximately $39,000. Ameritas Investment Partners Inc. grew its holdings in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after purchasing an additional 738 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Maze Therapeutics by 947.8% in the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares during the period. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of Maze Therapeutics in the third quarter worth $52,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.